These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19414728)

  • 1. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Taillibert S; Vincent LA; Granger B; Marie Y; Carpentier C; Guillevin R; Bellanger A; Mokhtari K; Rousseau A; Psimaras D; Dehais C; Sierra del Rio M; Meng Y; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2009 May; 72(18):1601-6. PubMed ID: 19414728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Chamberlain MC
    Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
    [No Abstract]   [Full Text] [Related]  

  • 3. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
    Bokstein F; Shpigel S; Blumenthal DT
    Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
    Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
    J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
    Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
    J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.